Most Read

Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks). Secondary

Halozyme CEO and president Dr Helen Torley said: “Since the signing of our collaboration with Bristol-Myers Squibb in September 2017, we have formed multiple joint program teams and

A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA, Darmstadt, Germany’s

AF affects approximately 350,000 patients in Canada. St. Michael’s Hospital staff cardiac electrophysiologist and University of Toronto cardiology division department director Dr Paul Dorian said: “Brinavess offers an important

An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. The agreement provides

In the pharmaceutical industry, clinical-trial data is of paramount importance for drug development, and must be backed up and protected against any potential mishaps. Therefore, a Hybrid Cloud

The partnership will enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases. This partnership leverages WuXi Biologics’ drug discovery, development and

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive

RPD designation for progeria and progeroid laminopathies enables priority review voucher (PRV) eligibility upon FDA approval of a rare pediatric disease product application for lonafarnib for these ultra-rare